ophthalmology

Merck Co headquarters

Biotech

Merck data raise fears $1.3B eye drug has ‘limited’ potential

A mix of undifferentiated efficacy and concerning safety led analysts to predict “limited competitive potential” in diabetic macular edema.

Nick Paul Taylor Oct 12, 2026 2:54am

merck

Merck sees pivotal victory for $3B eye disease prospect

Sep 24, 2026 8:15am

lighthouse

Beacon lights path to approval for vision loss gene therapy

Sep 21, 2026 2:00am

Regeneron booth at AACR 2026

Regeneron ends eye disease trial following safety review

Aug 17, 2026 2:30pm

Closeup of blue eye on black background

Bausch + Lomb gives up on glaucoma eye drop hopeful after fail

Jul 10, 2026 7:31am

horse horse riding lasso man on horse in shadows

Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet

Jun 24, 2026 7:00am